(888) 645-1617
Accepting Cases

Cipro, Levaquin & Avelox Lawsuits

Makers of fluoroquinolone antibiotics like Cipro, Levaquin and Avelox face hundreds of lawsuits over allegations that the companies’ warnings about nerve damage as a potential side effect of the drugs were inadequate.

*Please seek the advice of a medical professional before discontinuing the use of this drug.

If you or a loved one took a fluoroquinolone antibiotic and suffered one of the following complications, you may be entitled to compensation.

  • Aortic Aneurysm
  • Aortic Dissection
Suffering from complications due to Cipro, Levaquin or Avelox? We can help.

Number of LawsuitsMore than 1,000

Plaintiff InjuriesPeripheral neuropathy

DefendantsBayer Healthcare Pharmaceuticals, Inc.; Merck & Co, Inc.; Johnson & Johnson; Janssen Research & Development LLC; McKesson Corporation; Schering Corporation; and Bayer Corporation

Bellwether Trial DatesAvelox bellwether trial cases – Aug. 6, 2018, Oct. 8, 2018, Feb. 4, 2019, June 10, 2019; Cipro bellwether trial cases – Dec. 3, 2018 and April 8, 2019

Litigation Status Active

MDL LocationDistrict of Minnesota

Get A Free Case Review

Nearly 800 cases are currently pending in federal and state court involving fluoroquinolones. Fluoroquinolones such as Cipro, Levaquin and Avelox are potent antibiotics used to treat a variety of bacterial infections, including upper respiratory infections. People who filed the lawsuits were prescribed a fluoroquinolone and allege that it causes peripheral neuropathy, a condition that develops as a result of damage to the peripheral nerves.

Cause of Claim

Lawsuits allege Fluoroquinolones cause periperal neuropathy, a type of nerve damage.

They claim the defendants —namely Bayer Healthcare Pharmaceuticals Inc, Merck & Co Inc., Johnson & Johnson, Janssen Research & Development LLC, and Bayer Corporation — failed to adequately warn patients of this alleged side effect. The defendants, who developed, manufacture and market fluoroquinolones, deny that the drugs are defective or unreasonably dangerous. They also deny that their warnings were inadequate.

In August 2015, the U.S. Judicial Panel on Multidistrict Litigation ordered all federal neuropathy fluoroquinolone cases be transferred to the District of Minnesota for consolidated pretrial proceedings. The panel assigned the multidistrict litigation (MDL) to the Hon. John R. Tunheim. At the time, about 80 actions were pending in nearly 40 federal districts. Additional cases (some of which were transferred to the MDL) were also pending in state court in California, Pennsylvania, New Jersey and Oklahoma. At its peak, the federal MDL consisted of 1,036 total actions. Several were settled for confidential amounts, according to court documents.

Fluoroquinolones & Nerve Damage Risk

Peripheral neuropathy, or neuropathy, causes numbness, tingling, burning or pain — often in the hands and feet. According to lawsuits filed by plaintiffs, manufacturers of these antibiotics claimed the risk was rare and failed to warn patients and doctors that the nerve damage could be permanent.

Patient taking a NCV test
Due to inadequate fluoroquinolone warnings, patients developed permanent nerve damage while taking the drug

Plaintiffs claim drug labels misled patients and purposely used confusing language to hide the truth about permanent nerve damage. It wasn’t until August 2013 — after the FDA released an updated warning — that drug makers added information about rapid onset, irreversible peripheral neuropathy. The new label also removed the word “rare” from the warning about risk.

According to the FDA, previous neuropathy warnings in fluoroquinolone labels were weak and unclear. Specifically, the agency said older labels didn’t properly explain that neuropathy damage can be swift after taking the drugs and can be irreversible.

Fluoroquinolones with the potential to cause neuropathy include:

  • Avelox (moxifloxacin hydrochloride)
  • Cipro (ciprofloxacin)
  • Cipro XR (ciprofloxacin)
  • Factive (gemifloxacin mesylate)
  • Floxin (ofloxacin)
  • Levaquin (levofloxacin)
  • Maxaquin (lomefloxacin hydrochloride)
  • Noroxin (norfloxacin)
  • Proquin XR (ciprofloxacin hydrochloride)
  • Raxar (grepafloxacin hydrochloride)
  • Zagam (sparfloxacin)

Status of Fluoroquinolone Nerve Damage Litigation

As of March 2017, about 738 cases remained pending in the MDL. About 254 cases involve Bayer or Merck entities, and between 90 and 100 of those cases also involve a Janssen entity, according to court documents. An additional 17 cases were pending in Pennsylvania state court.

The federal court has scheduled bellwether trials in 2018 and 2019. These trials are intended for both sides to test their arguments, with the goal of moving the overall litigation toward resolution. During a February 21, 2017, status conference, counsel told the court that both sides made their bellwether selections, including four cases each involving Avelox and two cases each involving Cipro. Both parties selected the same two Cipro cases and agreed that they would proceed with 10 bellwether cases, including eight Avelox cases and the two Cipro cases.

The litigation is now in the discovery phase, which is when both sides disclose all relevant facts and documents to one another prior to trial.

Defendants Accused of Negligence, Failure to Warn

Court filings accuse defendants of several counts of wrongdoing. Most cases of this type claim negligence and failure to warn; other counts include strict liability and fraud.

Types of wrongdoing include:

Strict Liability

Lawsuits allege the defendants knew fluoroquinolones posed unreasonable risks but failed to include adequate warnings in labeling to notify patients and doctors. At all times, defendants knew their products could cause harm but continued to sell it, the complaints say.

Failure to Warn

Plaintiffs also claim the defendants “negligently and recklessly failed to warn of the nature and scope of the side effects” associated with fluoroquinolones like Cipro, Levaquin and Avelox — in particular, irreversible peripheral neuropathy.

Negligence

Drug companies have a duty to make sure their products are safe before selling them. According to the complaints, the defendants breached their duty when they negligently promoted, distributed, marketed and labeled the fluoroquinolone antibiotics. They failed to conduct appropriate pre- and post-marketing tests and surveillance to make sure the drug was safe, the plaintiffs allege.

Fraud

Plaintiffs also accuse drug companies of misrepresenting the safety and effectiveness of fluoroquinolones they manufactured. They actively concealed the dangers of the drugs, specifically irreversible peripheral neuropathy, according to the lawsuits.

Individual Nerve Damage Lawsuits

More than a dozen fluoroquinolone neuropathy cases are pending in state court in California. Plaintiffs claim after they took one or more of these powerful antibiotics, they were left with debilitating nerve pain. Some patients took antibiotics for illnesses like simple sinus infections that could have been treated with other types of antibiotics. Examples of fluoroquinolone neuropathy lawsuits filed in California include:

Kellerman v. Bayer

Sherri Kellerman filed a lawsuit against Bayer after she took Avelox and developed peripheral neuropathy. The lawsuit says her nerve damage was a “direct and proximate result of being prescribed and ingesting Avelox.” Kellerman’s complaint states that “Avelox is defective, dangerous to human health, unfit and unsuitable to be marketed and sold in commerce, and lacked proper warnings and directions as to the dangers associated with its use.”

Grossman v. Johnson & Johnson

According to her lawsuit, Karyn Joy Grossman took Levaquin – manufactured by Johnson & Johnson – and developed peripheral neuropathy. According to Grossman’s complaint, the defendant marketed and sold Levaquin even though it knew the drug could cause peripheral neuropathy and did not warn patients and doctors. She seeks punitive damages because of the defendant’s “deliberate disregard for the rights and safety of their consumers.”

Other Fluoroquinolone Litigation

Nerve damage is not the only alleged injury that has led to litigation against the makers of fluoroquinolones. Studies have also linked this type of drug to tendon ruptures and aortic aneurysm and dissection. A fluoroquinolone is also at the center of a lawsuit regarding racketeering.

Levaquin Tendon Rupture

Judge Tenheim also oversaw pretrial proceedings for a separate MDL involving the fluoroquinolone Levaquin. Plaintiffs in that MDL were prescribed Levaquin and allege that it causes tendon rupture. As with the neuropathy MDL, plaintiffs in the tendon rupture MDL claim the defendants, Johnson & Johnson and Ortho-McNeil Pharmaceutical Inc., failed to adequately warn of the side effect.

Tendon Trauma in Foot
Fluoroquinolones have been linked to an increased risk of tendinitis and tendon rupture

The plaintiffs began filing lawsuits in late 2006; the U.S. Judicial Panel on Multidistrict Litigation created the MDL in 2008. Around the same time the MDL began, the FDA first added a black box warning to fluoroquinolones for the increased risk of tendinitis and tendon rupture.

In November 2010, the first bellwether trial was tried against Ortho-McNeil Pharmaceutical Inc and resulted in a jury verdict in favor of the plaintiff. The jury awarded the plaintiff $700,000 in compensatory damages, which was later reduced to $630,000. The jury also awarded punitive damages in the amount of $1,115,000. The second and third bellwether trials were tried in June 2011 and January 2012, respectively. Both resulted in jury verdicts in favor of Johnson & Johnson and Ortho-McNeil Pharmaceutical Inc.

About 2,049 total actions were filed under the MDL. Court records show hundreds of cases ended in settlements. Others were transferred or remanded and subsequently dismissed. Only 10 remained pending as of March 2017.

Levaquin Racketeering

In 2016, five individuals sued former FDA Commissioner Margaret A. Hamburg, among others, seeking close to a billion dollars in damages. The plaintiffs claim Hamburg, her hedge-fund-executive husband and Johnson & Johnson conspired to increase profits by failing to warn about “the full extent of the devastating, life-threatening, and deadly effects of a highly dangerous pharmaceutical drug named Levaquin.”

The plaintiffs allege the defendants engaged in racketeering and violated the Federal RICO Act, a law typically used to prosecute organized crime.

Author

Emily Miller is an award-winning journalist who has held writing and editorial positions with numerous print and online publications around the U.S. She draws on her background as both a patient and a journalist to help readers understand complex health topics. Her most recent experience is in writing about litigation involving medicines that cause life-altering side effects.

View Sources
  1. U.S. District Court District of Minnesota. (2014, September 11).Final Pretrial Order and Suggestion of Remand. Retrieved from http://www.mnd.uscourts.gov/MDL-Levaquin/Pretrial_Minutes/2014/2014-0911-Final-PTO-and-suggestion-of-remand.pdf
  2. U.S. Judicial Panel on Multidistrict Litigation. (2015, August 17). Transfer Order. Retrieved from PACER.
  3. U.S. District Couty District of Minnesota. (2017, April 5). Retrieved from http://www.mnd.uscourts.gov/MDL-Fluoroquinolone/current-developments.shtml
  4. U.S. District Court District of Minnesota.(n.d.). Fluoroquinolone MDL | 15-MD-2642. Retrieved from http://www.mnd.uscourts.gov/MDL-Fluoroquinolone/index.shtml
  5. U.S. District Court District of Minnesota. (n.d.). Levaquin MDL | 08-MD-1943. Retrieved from http://www.mnd.uscourts.gov/MDL-Levaquin/index.shtml
  6. Do, T. (n.d.). Johnson & Johnson, former FDA commissioner among defendants in Levaquin lawsuit. Retrieved from http://www.abc2news.com/news/in-focus/johnson-johnson-former-fda-commissioner-among-defendants-in-levaquin-lawsuit
  7. Daneman, N. et al. (2015). Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ. Retrieved from http://bmjopen.bmj.com/content/5/11/e010077.full
  8. Boyles, S. (2015, October 7). Fluoroquinolones May Increase Aortic Aneurysm Risk. MedPage Today. Retrieved from http://www.medpagetoday.com/Cardiology/Prevention/53950
  9. Lee, C. et al. (2015). Risk of Aortic Dissection and Aortic Aneurysm in Patients Taking Oral Fluoroquinolone. JAMA. Retrieved from http://archinte.jamanetwork.com/article.aspx?articleid=2451282
  10. Boudin, M. (2015, February 25). Devastating side effects prompt local push to ban antibiotic. WCNC. Retrieved from http://www.wcnc.com/story/news/health/2015/02/24/devastating-side-effects-prompt-local-push-to-ban-antibiotic/23977183/
  11. FDA. (2008, July 8). Information for Healthcare Professionals: Fluoroquinolone Antimicrobial Drugs [ciprofloxacin (marketed as Cipro and generic ciprofloxacin), ciprofloxacin extended-release (marketed as Cipro XR and Proquin XR), gemifloxacin (marketed as Factive), levofloxacin (marketed as Levaquin), moxifloxacin (marketed as Avelox), norfloxacin (marketed as Noroxin), and ofloxacin (marketed as Floxin)]. Retrieved from http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126085.htm
  12. FDA, (2013, August 15). FDA Drug Safety Communication: FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection. Retrieved from http://www.fda.gov/Drugs/DrugSafety/ucm365050.htm
  13. Grossman v. Johnson & Johnson et al. (2014, August 6). Complaint for damages and demand for jury trial. United States District Court Northern District Of California San Francisco Division. Case No. 3:14-cv-03557.
  14. Kellerman v. Bayer et al. (2014, August 14). Complaint for damages and demand for jury trial. United States District Court Northern District Of California San Francisco Division. Case No. 3:14-cv-03680.
  15. Creative Commons. (n.d.). Levaquin. https://pillbox.nlm.nih.gov/assets/large/50458-0925-50_741B3A59.jpg
Free Cipro, Levaquin and Avelox Case Review